arrow
F

Francesco Schietroma

irccs policlinico gemelli
H指数:3
被引数:38

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-term survival and prognostic factors after repeated metastasectomies in metastatic colorectal cancer: a 15-years retrospective study

结直肠癌转移患者重复转移灶切除术后的长期生存及预后因素:一项15年回顾性研究

2025-12-010
PRE
Real-World Evidence of Regorafenib Dose Escalation Versus Fixed Dosing in Refractory Metastatic Colorectal Cancer: Results from the ReTrITA Study

真实世界证据:regorafenib剂量递增与固定剂量在难治性转移性结直肠癌中的比较:ReTrITA研究的结果

2025-10-140
OAAI
Prognostic impact and clinical management of pT4N0 colon cancer: data from a large, multicenter, international, real-world dataset

pT4N0结肠癌的预后影响与临床管理:来自大型、多中心、国际、真实世界数据集的数据

2025-07-150
OAAI
Venous Thromboembolic Risk Does Not Increase After a Third Dose of SARS-CoV-2 mRNA-BNT162b2 Vaccine in Cancer Patients Receiving Active Systemic Therapies: Updated Results from the Vax-On-Third-Profile Study

静脉血栓栓塞风险在癌症患者接受积极系统性治疗后接种第三剂SARS-CoV-2 mRNA-BNT162b2疫苗后不会增加:Vax-On-Third-Profile研究更新结果

2025-04-080
OA
The Impact of a Multidisciplinary Tumor Board (MDTB) in the Management of Colorectal Cancer (CRC)

多学科肿瘤委员会(MDTB)在结直肠癌(CRC)管理中的影响

2025-01-100
OA
Aflibercept-Based and Bevacizumab-Based Second Line Regimens in Patients with Metastatic Colorectal Cancer: Propensity Score Weighted-Analysis from a Multicenter Cohort

阿柏西普为基础和贝伐珠单抗为基础的二线方案在转移性结直肠癌患者中的应用:一项多中心队列研究的倾向性评分加权分析

2025-01-020
OAAI
Changes in clinical presentation, management, and survival outcomes in patients affected by colorectal cancer following COVID-19 pandemic
2024-11-012
OA
Homologous recombination (HR) and DNA damage repair (DDR) somatic alterations in metastatic colorectal cancer (mCRC): Results from the comprehensive genomic profiling (CGP) trial FPG500

同源重组(HR)和DNA损伤修复(DDR)体细胞改变在转移性结直肠癌(mCRC)中的研究:综合基因组分析(CGP)试验FPG500的结果

2024-09-010
PRE
The presence of liver metastases does not predict resistance to immunotherapy in proficient MMR metastatic colorectal cancer (mCRC): A secondary analysis of the AtezoTRIBE study
2024-06-010
PRE
Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Analysis
2024-04-131
OAAI
Medium to long-term effects of the COVID-19 pandemic on colorectal cancer diagnosis and management in Italy: Preliminary findings from an updated analysis of the real-world multicenter COVID-DELAY study
2023-10-010
PRE
Gut microbiome composition as predictor of the efficacy of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in metastatic colorectal cancer: A translational analysis of the AtezoTRIBE study
2023-06-010
OA
Aflibercept-based and bevacizumab-based second-line regimens in patients with RAS mutant metastatic colorectal cancer: Propensity score weighted-analysis from a multicenter cohort
2023-06-010
OA
Aflibercept-based and bevacizumab-based second-line regimens in patients with RAS/BRAF wild type metastatic colorectal cancer: Propensity score weighted-analysis from a multicenter cohort
2023-06-010
OAAI